Last reviewed · How we verify
NCT03788421
Comparison Between 2 Techniques for Bilateral Salpingectomy
NA trial testing LIGASURE in Sterility, Female in 51 participants. Completed in 1 September 2021.
1 January 2021
Quick facts
| Lead sponsor | Rambam Health Care Campus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 1 January 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- LIGASURE
- Clamping and suturing
Conditions studied
- Sterility, Female — all drugs for Sterility, Female →
Sponsor
Rambam Health Care Campus — full company profile →
Who can join
Adults 18 to 45, female only, with Sterility, Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A comparison between 2 techniques for bilateral salpingectomy during cesarean section. Primary outcomes are total operative time and bilateral completion of the randomized procedure. Secondary outcomes included surgical complications and post operation complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03788421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LIGASURE
Trials testing the same drug.
- NCT02628093 — A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery · NA · completed
Other recruiting trials for Sterility, Female
Currently open trials in the same condition.
- NCT05279560 — Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation · NA · active not recruiting
Other Rambam Health Care Campus trials
Trials by the same sponsor.
- NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
- NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
- NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
- NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
- NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03788421 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
- Last refreshed: 10 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03788421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing